TABLE 4.
Circulating endocannabinoids and ERCs and their NAPE and PI-2-AG (lipid-bound) precursors in plasma of six healthy human volunteers (n = 6)
| Free (ng/ml) | Lipid-bound (ng/ml) | Literature values (ng/ml) | ||
| Free | Lipid-bound | |||
| PEA | 2.51 ± 0.39 | 330 ± 53.8 | 0.48 (a), 1.5 (b), 2.1 (c), 4 (d), 4.3 (e) | 50.92 (b) |
| SEA | 2.03 ± 1.21 | 167 ± 30.3 | 0.62 (b), 1.2 (c) 2.1 (d), 3.3 (a) | 34.31 (b) |
| POEA | 0.11 ± 0.05 | 6.52 ± 0.9 | 0.17 (c), 20.9 (a) | — |
| VEA | 0.81 ± 0.20 | 26.1 ± 4.67 | 2.33 (f) | — |
| OEA | 1.24 ± 0.25 | 123 ± 20.5 | 0.54 (d), 1 (a), 1.5 (e), 1.98 (b), 3.1 (c) | 22.66 (b) |
| tVEA | <LOD | 4.3 ± 1.4 | — | — |
| EEA | <LOD | <LOD | — | — |
| tPeEA | <LOD | <LOD | — | — |
| ALEA | 0.05 ± 0.02 | 2.73 ± 0.77 | 0.04 (c), 0.21 (d) | — |
| DALEA | <LOD | <LOD | — | — |
| ETEA | <LOD | 0.47 ± 0.11 | — | — |
| EPEA | 0.02 ± 0.01 | 1.91 ± 0.93 | 0.03 (c), 0.1 (a) | — |
| DHEA | 0.26 ± 0.09 | 13.7 ± 6.7 | 0.41 (b), 0.44 (c), 0.46 (a) | 3.99 (b) |
| LEA | 0.49 ± 0.15 | 39.4 ± 9.79 | 1.23 (c), 2.54 (a), 17.97 (d) | — |
| GLEA | <LOD | 1 ± 0.4 | — | — |
| DGLEA | 0.04 ± 0.01 | 4.66 ± 1.58 | 0.12 (c) | — |
| AEA | 0.17 ± 0.03 | 22.1 ± 6.08 | 0.23 (d), 0.34 (e), 0.37 (b), 0.39 (c), 0.41, 0.5 (a) | 8.07 (b) |
| 2-AG | 0.63 ± 0.21 | 18.6 ± 5.1 | 0.57 (e), 0.72 (h), 0.89 (c), 9.4 (a), 1.1 (g) | — |
| 1-AG | 0.09 ± 0.07 | 1.58 ± 0.43 | 0.18 (e) | — |
| 2-LG | 2.31 ± 0.80 | 9.24 ± 2.92 | 7.8 (c), 15.7 (a), 27.6 (g) | — |
| 1-LG | 1.00 ± 0.29 | 1.61 ± 0.31 | — | — |
| 2-OG | 6.18 ± 3.95 | 15.7 ± 10.4 | 8.93 (c), 17.8 (g) | — |
| NE | <LOD | <LOD | — | — |
| NAGly | 0.25 ± 0.09 | <LOD | 0.61 (a) | — |